edwards lifesciences corp. - EW
EW
Close Chg Chg %
73.92 0.86 1.16%
Closed Market
74.78
+0.86 (1.16%)
Volume: 14.21M
Last Updated:
Dec 20, 2024, 3:59 PM EDT
Company Overview: edwards lifesciences corp. - EW
EW Key Data
| Open $73.27 | Day Range 72.97 - 75.27 |
| 52 Week Range 58.93 - 96.10 | Market Cap $43.60B |
| Shares Outstanding 589.80M | Public Float 579.56M |
| Beta 1.12 | Rev. Per Employee N/A |
| P/E Ratio 10.66 | EPS $6.95 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.50M |
EW Performance
| 1 Week | 2.03% | ||
| 1 Month | 6.14% | ||
| 3 Months | 11.94% | ||
| 1 Year | -1.35% | ||
| 5 Years | -5.06% |
EW Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
33
Full Ratings ➔
About edwards lifesciences corp. - EW
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
EW At a Glance
Edwards Lifesciences Corp.
1 Edwards Way
Irvine, California 92614
| Phone | 1-949-250-2500 | Revenue | 6.00B | |
| Industry | Medical Specialties | Net Income | 1.40B | |
| Sector | Health Technology | 2023 Sales Growth | 11.564% | |
| Fiscal Year-end | 12 / 2024 | Employees | 19,800 | |
| View SEC Filings |
EW Valuation
| P/E Current | 10.664 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 33.133 |
| Price to Sales Ratio | 7.738 |
| Price to Book Ratio | 6.892 |
| Price to Cash Flow Ratio | 51.872 |
| Enterprise Value to EBITDA | 25.119 |
| Enterprise Value to Sales | 7.591 |
| Total Debt to Enterprise Value | 0.015 |
EW Efficiency
| Revenue/Employee | 303,272.727 |
| Income Per Employee | 70,828.283 |
| Receivables Turnover | 7.175 |
| Total Asset Turnover | 0.68 |
EW Liquidity
| Current Ratio | 3.376 |
| Quick Ratio | 2.399 |
| Cash Ratio | 1.378 |
EW Profitability
| Gross Margin | 76.041 |
| Operating Margin | 27.806 |
| Pretax Margin | 26.614 |
| Net Margin | 23.355 |
| Return on Assets | 15.886 |
| Return on Equity | 22.516 |
| Return on Total Capital | 19.094 |
| Return on Invested Capital | 20.336 |
EW Capital Structure
| Total Debt to Total Equity | 10.45 |
| Total Debt to Total Capital | 9.461 |
| Total Debt to Total Assets | 7.422 |
| Long-Term Debt to Equity | 10.075 |
| Long-Term Debt to Total Capital | 9.122 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Edwards Lifesciences Corp. - EW
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 4.39B | 5.23B | 5.38B | 6.00B | |
Sales Growth
| +0.88% | +19.29% | +2.86% | +11.56% | |
Cost of Goods Sold (COGS) incl D&A
| 1.10B | 1.23B | 1.17B | 1.44B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 135.40M | 163.30M | 166.80M | 145.00M | |
Depreciation
| 130.00M | 155.60M | 161.10M | 138.90M | |
Amortization of Intangibles
| 5.40M | 7.70M | 5.70M | 6.10M | |
COGS Growth
| -4.87% | +11.55% | -4.79% | +23.26% | |
Gross Income
| 3.29B | 4.01B | 4.22B | 4.57B | |
Gross Income Growth
| +2.96% | +21.88% | +5.21% | +8.32% | |
Gross Profit Margin
| +74.94% | +76.57% | +78.31% | +76.04% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.99B | 2.40B | 2.51B | 2.90B | |
Research & Development
| 760.70M | 903.10M | 945.20M | 1.07B | |
Other SG&A
| 1.23B | 1.49B | 1.57B | 1.82B | |
SGA Growth
| -0.18% | +20.33% | +4.87% | +15.27% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 435.50M | (130.90M) | (1.60M) | 173.20M | |
EBIT after Unusual Expense
| 860.50M | 1.74B | 1.70B | 1.50B | |
Non Operating Income/Expense
| 78.40M | (14.50M) | 89.60M | 126.10M | |
Non-Operating Interest Income
| 23.40M | 17.40M | 35.50M | 67.20M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 22.20M | 24.80M | 26.20M | 24.50M | |
Interest Expense Growth
| -18.68% | +11.71% | +5.65% | -6.49% | |
Gross Interest Expense
| 22.20M | 24.80M | 26.20M | 24.50M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 916.70M | 1.70B | 1.77B | 1.60B | |
Pretax Income Growth
| -21.41% | +85.67% | +3.84% | -9.58% | |
Pretax Margin
| +20.90% | +32.53% | +32.84% | +26.61% | |
Income Tax
| 93.30M | 198.90M | 245.50M | 198.70M | |
Income Tax - Current - Domestic
| 71.60M | 150.30M | 429.70M | 375.40M | |
Income Tax - Current - Foreign
| 73.90M | 92.60M | 66.70M | 85.30M | |
Income Tax - Deferred - Domestic
| (21.90M) | (34.80M) | (246.60M) | (241.70M) | |
Income Tax - Deferred - Foreign
| (30.30M) | (9.20M) | (4.30M) | (20.30M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 823.40M | 1.50B | 1.52B | 1.40B | |
Minority Interest Expense
| - | - | - | (3.00M) | - |
Net Income
| 823.40M | 1.50B | 1.52B | 1.40B | |
Net Income Growth
| -21.35% | +82.55% | +1.25% | -7.85% | |
Net Margin Growth
| +18.77% | +28.73% | +28.28% | +23.35% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 823.40M | 1.50B | 1.52B | 1.40B | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 823.40M | 1.50B | 1.52B | 1.40B | |
EPS (Basic)
| 1.3225 | 2.4115 | 2.4586 | 2.3115 | |
EPS (Basic) Growth
| -21.06% | +82.34% | +1.95% | -5.98% | |
Basic Shares Outstanding
| 622.60M | 623.30M | 619.00M | 606.70M | |
EPS (Diluted)
| 1.303 | 2.3813 | 2.4382 | 2.3013 | |
EPS (Diluted) Growth
| -20.77% | +82.76% | +2.39% | -5.61% | |
Diluted Shares Outstanding
| 631.90M | 631.20M | 624.20M | 609.40M | |
EBITDA
| 1.43B | 1.77B | 1.87B | 1.81B | |
EBITDA Growth
| +9.06% | +23.91% | +5.38% | -2.92% | |
EBITDA Margin
| +32.63% | +33.90% | +34.73% | +30.22% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 78.28 | |
| Number of Ratings | 34 | Current Quarters Estimate | 0.551 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 2.57 | |
| Last Quarter’s Earnings | 0.67 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.51 | Next Fiscal Year Estimate | 2.448 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 27 | 23 | 21 | 29 |
| Mean Estimate | 0.55 | 0.59 | 2.57 | 2.45 |
| High Estimates | 0.57 | 0.62 | 2.60 | 2.55 |
| Low Estimate | 0.54 | 0.55 | 2.48 | 2.40 |
| Coefficient of Variance | 1.62 | 2.63 | 0.92 | 1.09 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 10 | 9 | 10 |
| OVERWEIGHT | 4 | 4 | 5 |
| HOLD | 20 | 20 | 17 |
| UNDERWEIGHT | 0 | 0 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Edwards Lifesciences Corp. - EW
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Edwards Lifesciences Corp. - EW
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 12, 2024 | Daniel J. Lippis CVP, JAPAC | 23,189 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $94.18 per share | 2,183,940.02 |
| Jul 12, 2024 | Daniel J. Lippis CVP, JAPAC | 4,530 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 12, 2024 | Daniel J. Lippis CVP, JAPAC | 23,689 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 1,072,637.92 |
| Jul 11, 2024 | David T. Feinberg Director | 2,308 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 11, 2024 | Donald E. Bobo CVP,Strategy/Corp Development | 55,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 11, 2024 | Donald E. Bobo CVP,Strategy/Corp Development | 46,936 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $93.29 per share | 4,378,659.44 |
| Jul 11, 2024 | Donald E. Bobo CVP,Strategy/Corp Development | 51,936 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 2,351,662.08 |
| Jun 21, 2024 | Scott B. Ullem CVP, Chief Financial Officer | 36,186 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $45.28 per share | 1,638,502.08 |
| Jun 21, 2024 | Scott B. Ullem CVP, Chief Financial Officer | 35,786 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $88.11 per share | 3,153,104.46 |
| Jun 21, 2024 | Scott B. Ullem CVP, Chief Financial Officer | 30,561 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $87.47 per share | 2,673,170.67 |
| Jun 21, 2024 | Scott B. Ullem CVP, Chief Financial Officer | 56,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 31, 2024 | Bernard J. Zovighian CEO; Director | 68,218 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $87.68 per share | 5,981,354.24 |
| May 22, 2024 | Scott B. Ullem CVP, Chief Financial Officer | 61,875 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 14, 2024 | Donald E. Bobo CVP,Strategy/Corp Development | 65,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 14, 2024 | Catherine M. Szyman CVP, Critical Care | 76,165 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.72 per share | 6,605,028.80 |
| May 14, 2024 | Jean-Luc Lemercier CVP, EMEACLA and JAPAC | 184,768 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.72 per share | 16,023,080.96 |
| May 14, 2024 | Larry L. Wood Global President TAVR & Surg | 223,526 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.72 per share | 19,384,174.72 |
| May 14, 2024 | Robert W. A. Sellers SVP, Corporate Controller | 17,081 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.72 per share | 1,481,264.32 |
| May 14, 2024 | Donald E. Bobo CVP,Strategy/Corp Development | 46,936 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.72 per share | 4,070,289.92 |
| May 14, 2024 | Daveen Chopra CVP, TMTT | 30,583 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $86.72 per share | 2,652,157.76 |
Edwards Lifesciences Corp. in the News
Medical-device makers gain amid return to normalcy
Many of the top large-cap device makers reported relatively rosy fourth-quarter earnings while issuing 2023 guidance that was above analyst expectations.